Join Rini Mehta to get the fundamental view of the trading week.

- Weekly pick: Sumitomo Chem - The company reported strong revenue growth of 26.3% Year-on-Year (YoY) due to robust demand from the international market and pickup in demand from the domestic market post strong monsoon and positive outlook on Rabi season.

- Other picks: Sun Pharma - We revisit Ilumya’s revenue potential in lieu of expected further competition in the US plaque psoriasis market with two key launches in CY2022 – UCB’s Bimekizumab and BMS’ Deucravacitinib.